MapLight Therapeutics (NASDAQ: MPLT) grants RSUs and options to director Walker

Rhea-AI Filing Summary

MapLight Therapeutics director Maria C. Walker received new equity awards as part of non-employee director compensation. She was granted 3,932 restricted stock units, each representing one share of voting common stock. These RSUs vest on the earlier of June 23, 2027 or the company’s next annual stockholder meeting, subject to her continuous service.

Walker also received a stock option for 14,902 shares of voting common stock at an exercise price of $28.64 per share, expiring on June 22, 2036, with the same vesting schedule. After the RSU grant, her direct holdings of voting common stock total 62,703 shares. These are compensation-related awards rather than open-market purchases.

Insights

Equity compensation analyst

Routine director equity grants with time-based vesting and no cash buying.

Director Maria C. Walker received 3,932 RSUs and an option over 14,902 shares at an exercise price of $28.64, all under MapLight Therapeutics’ 2025 Equity Incentive Plan and non-employee director compensation policy.

These awards vest on the earlier of June 23, 2027 or the next annual stockholder meeting, conditioned on continuous service. This structure aligns director incentives with shareholders over time and represents standard, non-cash compensation rather than discretionary market buying or selling.

With 62,703 voting common shares held directly after the RSU grant and a new option position expiring in 2036, Walker maintains meaningful long-term exposure. The filing does not indicate any share disposals, so the signal is routine and primarily governance- and compensation-related.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Walker Maria C

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	14,902	$0.00	--
Grant/Award	Voting Common Stock	3,932	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 14,902 shares (Direct, null); Voting Common Stock — 62,703 shares (Direct, null)

Footnotes (1)

1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.

Key Figures

RSU grant size: 3,932 RSUs Option grant size: 14,902 shares Option exercise price: $28.64 per share +3 more

6 metrics

RSU grant size 3,932 RSUs Granted June 23, 2026 under 2025 Equity Incentive Plan

Option grant size 14,902 shares Stock option for Voting Common Stock granted June 23, 2026

Option exercise price $28.64 per share Exercise price for 14,902-share stock option

Option expiration June 22, 2036 Expiration date of stock option grant

Shares held after grant 62,703 shares Direct voting common stock holdings after RSU grant

RSU vesting date trigger Earlier of June 23, 2027 or next annual meeting Applies to both RSUs and stock option vesting

Key Terms

restricted stock units ("RSUs"), 2025 Equity Incentive Plan, Continuous Service, non-employee director compensation policy, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2025 Equity Incentive Plan financial

"granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan")"

Continuous Service financial

"subject to the Continuous Service (as defined in the Plan) of the Reporting Person"

non-employee director compensation policy financial

"This grant was made pursuant to the Issuer's non-employee director compensation policy."

stock option financial

"Represents a stock option granted pursuant to the Plan."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 05:52 PM Accepted by SEC EDGAR 06/25/2026 - 05:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walker Maria C

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	06/23/2026		A		3,932(1)	A	$0(2)	62,703	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$28.64	06/23/2026		A		14,902		(3)	06/22/2036	Voting Common Stock	14,902	$0	14,902	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.

2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.

3. Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Maria C. Walker receive from MapLight Therapeutics (MPLT)?

Maria C. Walker received 3,932 restricted stock units and a stock option for 14,902 shares of voting common stock. Both awards were granted under the 2025 Equity Incentive Plan as part of MapLight’s non-employee director compensation policy.

What is the vesting schedule for Maria C. Walker’s new MPLT RSUs and options?

Both the 3,932 RSUs and 14,902-share option vest on the earlier of June 23, 2027, or MapLight Therapeutics’ next annual stockholder meeting. Vesting is conditioned on Walker’s Continuous Service with the company through the applicable vesting date.

What is the exercise price and expiration date of Maria C. Walker’s new MPLT stock option?

The newly granted stock option covers 14,902 shares of voting common stock at an exercise price of $28.64 per share. The option expires on June 22, 2036, giving a long-dated window for potential exercise once vesting conditions are satisfied.

How many MPLT shares does Maria C. Walker own after this Form 4 transaction?

After the RSU grant, Maria C. Walker directly holds 62,703 shares of MapLight Therapeutics voting common stock. This figure reflects her direct non-derivative holdings and shows her ongoing equity exposure alongside the new RSU and option awards.

Are Maria C. Walker’s MPLT equity awards open-market purchases or compensation grants?

The Form 4 shows compensation-related grants, not open-market purchases. Both the 3,932 RSUs and 14,902-share stock option were awarded at a $0.00 transaction price under MapLight’s 2025 Equity Incentive Plan and non-employee director compensation policy.